Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | N. Sato et al., Int. Immunol., Dec 2005; 17: 1543 - 1552 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene SI | publication | R. Romano et al., Cell. and Mol. Life Sci., 2021, 78: 351–372, 78:351–372, doi.org/10.1007/s00018-020-03510-1 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | A. Fathinajafabadi et al., PLoS ONE, 2014, 9(2): e87898, doi:10.1371/journal.pone.0087898 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | K. Fortschegger et al., Mol. Cancer Res., Apr 2014; 12: 595 - 606 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Mahmoodi et al., IET Nanobiotechnol., 2017, 11 (8): 995-1004 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | K. J. Choi et al., Cancer Res., Apr 2007; 67: 3654 - 3662 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene | publication | S.-B. M. Varda et al., 2012, WO 2007/043049 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | K. Klement et al., J. Cell Biol., Dec 2014; 207: 717 - 733 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | oligonucleotide | DOTAP | publication | A. Avinó et al., Protocols in Nucleic Acid Chemistry, 2020, 77: e78, doi: 10.1002/cpnc.78 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | M. G. Aluigi et al., Eur J Histochem, Oct 2007; 51(4): 301-4 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | E. Bernardinelli et al., PLOSONE, doi.org/10.1371/journal.pone.0179591 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | J. Suchánková et al., Europ. J. of Histochemistry, 2014; 58:2389, doi:10.4081/ejh.2014.2389 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | S. de la Fuente et al., Biochem. J., 2014, 458: 33-40, doi:10.1042/BJ20131025 | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Hoffmeister et al., J. Biol. Chem., Jan 2008; 283: 2297 - 2306 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M.-S. Jang et al., J. Biol. Chem., Nov 2008; 283: 32344 - 32351 | Link | ||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Schindler et al., J. Virol., Oct 2003; 77: 10548 - 10556 | Link | |||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | J. Münch et al., J. Virol., Aug 2005, 79 (16), 10547-10560 | Link | |||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | F. Kirchhoff et al., J. Virol., Jul 2004; 78: 6864 - 6874. | Link | |||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Brenner et al., J. Virol., May 2006; 80: 4469 - 4481 | Link | |||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Schindler et al., J. Virol., Oct 2004; 78: 10588 - 10597 | Link | |||
HeLa-229 |
Human cervix adenocarcinoma cell line (derivat of HeLa) | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | publication | D. Kaul et al., Blood Cells, Molecules and Diseases, 2015, 55: 89-93, doi.org/10.1016/j.bcmd.2015.05.001 | ||||
HeLa-229 |
Human cervix adenocarcinoma cell line (derivat of HeLa) | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | K2 Transfection System | publication | D. Kaul et al., Blood Cells, Molecules and Diseases, 2015, 55: 89-93, doi.org/10.1016/j.bcmd.2015.05.001 | |||
HeLa-229 |
Human cervix adenocarcinoma cell line (derivat of HeLa) | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | publication | A. Garg et al., Blood Cells, Molecules and Diseases, 2015, 55: 248-254, doi.org/10.1016/j.bcmd.2015.07.009 | ||||
HeLa-ABCA1-GFP |
Human cervix adenocarcinoma cell line (derivat of HeLa) | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | N. Mukhamedova et al., Methods Mol. Biol., 2016 ; 1354: 281-292; doi:10.1007/978-1-4939-3046-3_19 | ||||
HeLa-DR-13–9 |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | B. Haynesa et al., Biochim Biophys Acta Mol Basis Dis., 2020,1866(1): 165561, doi:10.1016/j.bbadis | Link |